Dissolvable Microneedle Delivery of a Replication-Deficient Orthopoxvirus Vaccine: Formulation Screening and Immunogenicity Evaluation for Monkeypox Prevention

Read full text Summarise with VIRAT
Authors: Bin Wang, Kehui Wang, Zhe Xu, Weihua Liu, Xianhuang Li, Linhao Li, Renhui Zhou, Xingyue Du, Jin Jin, Yaqing Xu, Rihui Qin, Xiong Liu
+2 more Dayang Zou, Wei Liu
Cited by: 0
References: 45

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Background: The global spread of monkeypox virus (MPXV) highlights an urgent need for thermostable and easily administrable vaccines. Current orthopoxvirus vaccines are limited by cold-chain dependence and inconvenient injection-based delivery. Objectives: This study aimed to develop a dissolvable microneedle (DMN) vaccine against monkeypox based on a replication-deficient orthopoxvirus platform, through systematic formulation screening, stabilization mechanism exploration, and rigorous in vivo immunogenicity evaluation. Methods: A film-based approach was adopted for efficient, high-throughput formulation screening and thermostability assessment. NTV was mixed with excipients and dried into solid films. Stability was monitored via RT-qPCR after storage at 4 °C to 40 °C. The lead formulation was physically characterized, then used to fabricate MVA-BN-loaded DMN patches, which were further evaluated for in vivo immunogenicity via immunization in BALB/c mice. Results: The optimal formulation F2 (containing dextran, L-threonine, and BSA/HSA) showed a potency loss of only ~1 log10 after 2 months at 25 °C, and

Fields of Study & Subjects

Advancements in Transdermal Drug Delivery Poxvirus research and outbreaks Intramuscular injections and effects

Publication details

Journal / source
Vaccines
Volume
14
Issue
3
Pages
276–276
Publication date
20 March 2026
Language
EN